Classical Hodgkin lymphoma. Issue 10310 (23rd October 2021)

• Record Type: Journal Article
• Authors: Brice, Pauline; de Kerviler, Eric; Friedberg, Jonathan W
• Is Part Of: Lancet. Volume 398:Issue 10310(2021)
• Page Start: 1518
• Page End: 1527
• Publication Date: 2021-10-23
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Medicine; Electronic journals; Periodicals; 610.5
• DOI: 10.1016/S0140-6736(20)32207-8
• Languages: English
• ISSNs: 0140-6736

Abstract

Summary: Classical Hodgkin lymphoma is one of the more frequent lymphomas and is generally considered a highly curable disease with standard first-line chemotherapy and radiotherapy in some cases. Despite these outstanding results, major problems remain unresolved. First, there are still patients who will not be cured with front-line regimens and, second, many patients who are cured of classical Hodgkin lymphoma continue to die prematurely due to the late toxic effects of their therapy. Because the median age of patients with classical Hodgkin lymphoma is in the mid-30s, the disease's impact on the number of years lost from productive life is remarkable. In recent years, the gold standard of chemotherapy (often combined with radiotherapy) has changed, with the approval of immunotherapy mostly in relapse settings.